# miR-4429 inhibits ccRCC proliferation, migration, and invasion by directly targeting CD274

**Authors:** GuangYi Hong, YiKun Wu, ShiYu Huang, Yang Hu, Ying Zhang, CiCi Guo, Hua Shi, ShuXiong Xu

PMC · DOI: 10.1007/s12672-024-01055-4 · Discover Oncology · 2024-05-27

## TL;DR

This study shows that miR-4429 reduces kidney cancer growth and spread by targeting CD274 and affecting a key signaling pathway.

## Contribution

miR-4429 is newly identified as a tumor suppressor in ccRCC by directly targeting CD274 and modulating PI3K/AKT signaling.

## Key findings

- miR-4429 is down-regulated in ccRCC tissues and inhibits cancer cell proliferation, migration, and invasion.
- CD274 is a direct target of miR-4429 and is up-regulated in ccRCC tissues.
- miR-4429 regulates the PI3K/AKT signaling pathway, offering a potential therapeutic target for ccRCC.

## Abstract

Clear cell renal cell carcinoma (ccRCC) is one of the most aggressive urological malignancies and a highly immunogenic cancer. Yet, its pathogenesis is still not fully understood. This study analyzed the role of the miR-320 family in ccRCC using bioinformatics algorithms and a series of in vitro experiments. miR-4429 was found to be significantly down-regulated in ccRCC tissues and cell lines, while overexpression of miR-4429 significantly inhibited renal cancer cell proliferation, migration, and invasion in vitro. In addition, the UALCAN database, immunohistochemistry, and protein blotting results showed that CD274 expression was up-regulated in ccRCC tissues and correlated with higher histologic grading. Dual luciferase assay indicated that CD274 was a direct target of miR-4429. Overexpression of miR-4429 in 786-O, Caki-2 cells significantly inhibited CD274 expression. KEGG results indicated that the potential target function of miR-4429 was associated with the PI3K/AKT signaling pathway, and protein blotting verified the results. In summary, this data shows that miR-4429 targets CD274 and inhibits ccRCC proliferation, migration, and invasion by regulating PI3K/AKT signaling, thus potentially providing a promising therapeutic target and prognostic biomarker for renal cell carcinoma patients.

The online version contains supplementary material available at 10.1007/s12672-024-01055-4.

## Linked entities

- **Genes:** MIR4429 (microRNA 4429) [NCBI Gene 100616469], CD274 (CD274 molecule) [NCBI Gene 29126]
- **Diseases:** clear cell renal cell carcinoma (MONDO:0005005), ccRCC (MONDO:0007763)

## Full-text entities

- **Genes:** AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, MIR4429 (microRNA 4429) [NCBI Gene 100616469] {aka mir-4429}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}
- **Diseases:** urological malignancies (MESH:D014571), cancer (MESH:D009369), renal cancer (MESH:D007680), Clear cell renal cell carcinoma (MESH:D002292)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** Caki-2 — Homo sapiens (Human), Papillary renal cell carcinoma, Cancer cell line (CVCL_0235), 786-O — Homo sapiens (Human), Renal cell carcinoma, Cancer cell line (CVCL_1051)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11130097/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11130097/full.md

## References

29 references — full list in the complete paper: https://tomesphere.com/paper/PMC11130097/full.md

---
Source: https://tomesphere.com/paper/PMC11130097